Dr. Satian Pooprasert, Managing Director of Praram 9 Hospital Public Company Limited (SET: PR9), stated that the company’s 2Q25 performance was satisfactory with a net profit of THB 182 million, an increase of 30.8% YoY from THB 139.1 million, and total revenue of THB 1.29 billion, an increase of 18.1% YoY from THB 1.09 billion. Meanwhile, the revenue from outpatient departments (OPD) were THB 689.6 million, while revenue from in-patient departments (IPD) were THB 587.5 million.
During the second quarter, PR9 continued to exhibit annualized revenue and profit growth due to its strategy to focus on expanding international patient base, especially those from the Middle East. These patients needed medical specialists and complex disease medical services, which the company was prepared for due to its specialised medical teams, technologies, modern innovative medical practices, as well as their reasonable prices.
PR9 generated a total medical revenue of THB 1.27 billion, an increase of 17.9% YoY from THB 1.08 billion. The revenue from OPD and IPD increased by 5.9% and 35.8% YoY, respectively, due to the company’s readiness in its medical teams and equipment that increased its capability to treat complex disease.
Furthermore, the revenue from international patients also increased by 109% YoY due to “Fly-in” patient groups, especially those from the Middle East, while the revenue from domestic patients increased only 1.7% YoY. Nonetheless, the revenue proposition from international and domestic patients have changed to 27% and 73% of the total revenue from medical business, respectively.
As for performance in the first half of the year, PR9 generated a net profit of THB 382.4 million, an increase of 28.3% YoY from THB 298.1 million, and a total revenue of THB 2.54 billion, an increase of 17% YoY from THB 2.17 billion. THB 2.51 billion of the total revenue was medical revenue, which increased by 16.8% YoY, resulting from the growth of OPD and IPD’s revenues that increased by 5.2% and 34%, respectively.
If compared by nationality, the revenue from foreign patients had increased by 98.6%, aligning with its strategy to focus on expanding international patient base, while the revenue from domestic patients increased only 2.3%. Nonetheless, the revenue proposition from international and domestic patients have changed to 26% and 74% of the total revenue from medical business, respectively.
Dr. Satian stated that PR9’s 2Q25 performance is at a satisfactory level due to the increase of foreign patients and its effective cost management. The company speculated that this year, the business will continue to generate strong growth.
